-
Intensive home treatment in different settings Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-30 Claire Henderson
Abstract not available
-
The effectiveness of intensive home treatment as a substitute for hospital admission in acute psychiatric crisis resolution in the Netherlands: a two-centre Zelen double-consent randomised controlled trial Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-30 Jurgen Cornelis, Ansam Barakat, Matthijs Blankers, Jaap Peen, Nick Lommerse, Merijn Eikelenboom, Jeroen Zoeteman, Henricus Van, Aartjan T F Beekman, Jack Dekker
Background Although de-institutionalisation has been underway for decades, admission to hospital followed by low-intensity outpatient care remains the usual treatment for patients with an acute psychiatric crisis. Intensive home treatment has been developed for patients in a severe psychiatric crisis as an alternative to inpatient care. This study aimed to evaluate the potential of intensive home treatment
-
An Intersectional Approach to Ethnoracial Disparities in Pathways to Care Among Individuals With Psychosis in Coordinated Specialty Care. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-29 Els van der Ven,Nev Jones,Natalie Bareis,Jennifer M Scodes,Renald Dambreville,Hong Ngo,Chackupurackal M Mathai,Iruma Bello,Gonzalo Martínez-Alés,Franco Mascayano,Rufina J Lee,Wim Veling,Deidre M Anglin,Roberto Lewis-Fernandez,Ezra S Susser,Michael T Compton,Lisa B Dixon,Melanie M Wall
Importance Intersecting factors of social position including ethnoracial background may provide meaningful ways to understand disparities in pathways to care for people with a first episode of psychosis. Objective To examine differences in pathways to care by ethnoracial groups and by empirically derived clusters combining multiple factors of social and clinical context in an ethnoracially diverse
-
Brain Wellness "Spas"-Anticipating the Off-label Promotion of Psychedelics. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-29 Anna Wexler,Dominic Sisti
-
Convergence and Divergence of Rare Genetic Disorders on Brain Phenotypes: A Review. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-29 Armin Raznahan,Hyejung Won,David C Glahn,Sébastien Jacquemont
Importance Rare genetic disorders modulating gene expression-as exemplified by gene dosage disorders (GDDs)-represent a collectively common set of high-risk factors for neuropsychiatric illness. Research on GDDs is rapidly expanding because these variants have high effect sizes and a known genetic basis. Moreover, the prevalence of recurrent GDDs (encompassing aneuploidies and certain copy number variations)
-
Bridging Knowledge Gaps in the Diagnosis and Management of Neuropsychiatric Sequelae of COVID-19. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-29 Jennifer A Frontera,Naomi M Simon
Importance Neuropsychiatric symptoms have been reported as a prominent feature of postacute sequelae of COVID-19 (PASC), with common symptoms that include cognitive impairment, sleep difficulties, depression, posttraumatic stress, and substance use disorders. A primary challenge of parsing PASC epidemiology and pathophysiology is the lack of a standard definition of the syndrome, and little is known
-
Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-27 Ebenezer Oloyede, Eromona Whiskey, Cecilia Casetta, Olubanke Dzahini, Danielle Dunnett, Shreyans Gandhi, Fiona Gaughran, Sukhi Shergill, Philip McGuire, James H MacCabe, David Taylor
Background Clozapine is uniquely effective in treatment-resistant psychosis. In the UK, patients must discontinue clozapine indefinitely if they are placed on the Central Non-Rechallenge Database (CNRD) after their haematological parameters fall below particular thresholds. Under exceptional circumstances, patients can be rechallenged on clozapine under an off-licence agreement. In the USA in 2015
-
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am. J. Psychiatry (IF 19.242) Pub Date : 2022-06-27 Steven M Paul,Samantha E Yohn,Michael Popiolek,Andrew C Miller,Christian C Felder
Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that
-
Antipsychotic maintenance treatment versus dose reduction: how the story continues Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-23 Iris E C Sommer, Mark Horowitz, Kelly Allott, Helene Speyer, Marieke J H Begemann
Abstract not available
-
Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-23 Giovanni Ostuzzi, Giovanni Vita, Federico Bertolini, Federico Tedeschi, Beatrice De Luca, Chiara Gastaldon, Michela Nosé, Davide Papola, Marianna Purgato, Cinzia Del Giovane, Christoph U Correll, Corrado Barbui
Background Although antipsychotic maintenance treatment is widely recommended to prevent relapse in chronic psychoses, evidence-based guidelines do not provide clear indications on different maintenance treatment strategies, including continuing the antipsychotic at standard doses, reducing the dose, switching to another antipsychotic, or even stopping the antipsychotic. We aimed to compare the effectiveness
-
The Effectiveness of 6 versus 12 Months of Dialectical Behavior Therapy for Borderline Personality Disorder: A Noninferiority Randomized Clinical Trial Psychother. Psychosom. (IF 25.617) Pub Date : 2022-06-23 Shelley F. McMain, Alexander L. Chapman, Janice R. Kuo, Katherine L. Dixon-Gordon, Timothy Henry Guimond, Cathy Labrish, Wanrudee Isaranuwatchai, David L. Streiner
Introduction: Evidence-based psychotherapies for borderline personality disorder (BPD) are lengthy, posing a barrier to their access. Brief psychotherapy may achieve comparable outcomes to long-term psychotherapy for BPD. Evidence is needed regarding the comparative effectiveness of short- versus long-term psychotherapy for BPD. Objective: The aim was to determine if 6 months of Dialectical Behavior
-
Racial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-22 Ayana Jordan, Stephanie Quainoo, Charla Nich, Theresa A Babuscio, Melissa C Funaro, Kathleen M Carroll
Reports from uncontrolled trials and surveys suggest that there are disparities in substance-use outcomes for minoritised racial and ethnic populations, yet few of these disparities have emerged from randomised clinical trials (RCTs). We conducted a systematic review of RCTs published in English of Black or Latinx adults with any non-nicotine substance use disorder that reported rates of treatment
-
Persistent Dissociation and Its Neural Correlates in Predicting Outcomes After Trauma Exposure Am. J. Psychiatry (IF 19.242) Pub Date : 2022-06-22 Lauren A.M. Lebois, Nathaniel G. Harnett, Sanne J.H. van Rooij, Timothy D. Ely, Tanja Jovanovic, Steven E. Bruce, Stacey L. House, Caitlin Ravichandran, Nathalie M. Dumornay, Katherine E. Finegold, Sarah B. Hill, Julia B. Merker, Karlye A. Phillips, Francesca L. Beaudoin, Xinming An, Thomas C. Neylan, Gari D. Clifford, Sarah D. Linnstaedt, Laura T. Germine, Scott L. Rauch, John P. Haran, Alan B. Storrow
Objective: Dissociation, a disruption or discontinuity in psychological functioning, is often linked with worse psychiatric symptoms; however, the prognostic value of dissociation after trauma is inconsistent. Determining whether trauma-related dissociation is uniquely predictive of later outcomes would enable early identification of at-risk trauma populations. The authors conducted the largest prospective
-
Integrating HIV and substance misuse services: a person-centred approach grounded in human rights Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-21 Victoria Haldane, Anne-Sophie Jung, Chuan De Foo, Pami Shrestha, Elena Urdaneta, Eva Turk, Juan I Gaviria, Jesus Boadas, Kent Buse, J Jaime Miranda, Steffanie A Strathdee, Ashley Barratt, Michel Kazatchkine, Martin McKee, Helena Legido-Quigley
Integrating HIV-related care with treatment for substance use disorder provides an opportunity to better meet the needs of people living with these conditions. People with substance use disorder are rendered especially vulnerable by prevailing policies, structural inequalities, and stigmatisation. In this Series paper we analyse existing literature and empirical evidence from scoping reviews on integration
-
Integrating mental health and substance use treatment with HIV care for people experiencing homelessness Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-21 Cheyenne M Garcia, Margot B Kushel
Abstract not available
-
Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia: A Systematic Review and Network Meta-analysis. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-22 Ping-Tao Tseng,Bing-Syuan Zeng,Chao-Ming Hung,Chih-Sung Liang,Brendon Stubbs,Andre F Carvalho,Andre R Brunoni,Kuan-Pin Su,Yu-Kang Tu,Yi-Cheng Wu,Tien-Yu Chen,Dian-Jeng Li,Pao-Yen Lin,Chih-Wei Hsu,Yen-Wen Chen,Mein-Woei Suen,Kazumi Satogami,Shun Takahashi,Ching-Kuan Wu,Wei-Cheng Yang,Yow-Ling Shiue,Tiao-Lai Huang,Cheng-Ta Li
Importance Negative symptoms have a detrimental impact on functional outcomes and quality of life in people with schizophrenia, and few therapeutic options are considered effective for this symptomatic dimension. Studies have suggested that noninvasive brain stimulation (NIBS) interventions may be effective in treating negative symptoms. However, the comparative efficacy of different NIBS protocols
-
An Editor’s Journey Ends, but the Journal’s Mission Continues Psychother. Psychosom. (IF 25.617) Pub Date : 2022-06-20 Giovanni A. Fava
Psychother Psychosom
-
Shifting paradigms Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 The Lancet Psychiatry
Abstract not available
-
Long-term mental health impacts of wounded UK combat personnel Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Lisa Dell
Abstract not available
-
Why is the educational attainment of people with schizophrenia lagging so far behind? Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Eóin Killackey
Abstract not available
-
Pathways to depressive and anxiety disorders during and after the COVID-19 pandemic Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 J C Lokman, C L Bockting
Abstract not available
-
Real-world effectiveness studies of low doses of antipsychotics Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Fabrice Berna, Benoit Schorr, Hervé Javelot, Ludovic C Dormegny-Jeanjean, Jack R Foucher
Abstract not available
-
Real-world effectiveness studies of low doses of antipsychotics – Authors' reply Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Heidi Taipale, Antti Tanskanen, Christoph U Correll, Jari Tiihonen
Abstract not available
-
Clozapine and the risk of haematological malignancies Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Jose de Leon, Carlos De las Cuevas, Emilio J Sanz, Can-Jun Ruan, Christoph U Correll
Abstract not available
-
Clozapine and the risk of haematological malignancies Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Peter FJ Schulte, Dan Cohen, Selene RT Veerman, Bert Bakker, Jan PAM Bogers
Abstract not available
-
Clozapine and the risk of haematological malignancies – Authors' reply Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Jari Tiihonen, Antti Tanskanen, J Simon Bell, Jessica L Dawson, Vesa Kataja, Heidi Taipale
Abstract not available
-
Unbalanced appraisal of psychosocial versus antipsychotic literature Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Mark Abie Horowitz, Klaus Munkholm, Joanna Moncrieff
Abstract not available
-
Unbalanced appraisal of psychosocial versus antipsychotic literature – Authors’ reply Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Sameer Jauhar, Stephen M Lawrie
Abstract not available
-
Peer support for discharge from inpatient mental health care Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Peter Phalen, Rebecca Miller, Barbara Frampton, Nev Jones, Karen Machin, Diana Rose, Hannah Stewart, Michelle Colder Carras
Abstract not available
-
Peer support for discharge from inpatient mental health care – Authors' reply Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Steve Gillard, Sally Barlow, Stephen Bremner, Rhiannon Foster, Sarah Gibson, Lucy Goldsmith, Andrew Healey, Mike Lucock, Jacqueline Marks, Akshaykumar Patel, Shalini Patel, Stefan Priebe, Miles Rinaldi, Alan Simpson, Michael Ussher, Sarah White
Abstract not available
-
Gambling harms and gambling disorder research funding Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Sian M Griffiths
Abstract not available
-
Diagnostic labels: the problem is the signified not the signifier Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Fritz Handerer, Peter Kinderman, Sara Tai
Abstract not available
-
DSM-5-TR turns normal grief into a mental disorder Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Joanne Cacciatore, Allen Francis
Abstract not available
-
Digital psychological first aid in humanitarian contexts Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Richard Armitage
Abstract not available
-
Laura Fischer: the art and science of transforming trauma Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Jules Morgan
Abstract not available
-
Boston, USA Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 David Haosen Xiang
Abstract not available
-
Mental health outcomes of male UK military personnel deployed to Afghanistan and the role of combat injury: analysis of baseline data from the ADVANCE cohort study Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Daniel Dyball, Alexander N Bennett, Susie Schofield, Paul Cullinan, Christopher J Boos, Anthony M J Bull, Simon Wessely, Sharon A M Stevelink, Nicola T Fear
Background The long-term psychosocial outcomes of UK armed forces personnel who sustained serious combat injuries during deployment to Afghanistan are largely unknown. We aimed to assess rates of probable post-traumatic stress disorder (PTSD), depression, anxiety, and mental health-associated multimorbidity in a representative sample of serving and ex-serving UK military personnel with combat injuries
-
The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-16 Nicolás A Crossley, Luz María Alliende, Leticia S Czepielewski, David Aceituno, Carmen Paz Castañeda, Camila Diaz, Barbara Iruretagoyena, Carlos Mena, Cristian Mena, Juan Pablo Ramirez-Mahaluf, Angeles Tepper, Javiera Vasquez, Lais Fonseca, Viviane Machado, Camilo E Hernández, Cristian Vargas-Upegui, Gladys Gomez-Cruz, Luis F Kobayashi-Romero, Ary Gadelha
Background Educational attainment is associated with wellbeing and health, but patients with schizophrenia achieve lower levels of education than people without. Several effective interventions can ameliorate this situation. However, the magnitude of the education gap in schizophrenia and its change over time are unclear. We aimed to reconstruct the trajectories of educational attainment in patients
-
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial Am. J. Psychiatry (IF 19.242) Pub Date : 2022-06-15 Didier Jutras-Aswad, Bernard Le Foll, Keith Ahamad, Ron Lim, Julie Bruneau, Benedikt Fischer, Jürgen Rehm, T. Cameron Wild, Evan Wood, Suzanne Brissette, Lea Gagnon, Jill Fikowski, Omar Ledjiar, Benoit Masse, M. Eugenia Socias, for the OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Objective: Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder. Methods: This seven-site, pan-Canadian
-
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries Am. J. Psychiatry (IF 19.242) Pub Date : 2022-06-15 Andrew D. Mosholder, Yong Ma, Sandia Akhtar, Gerald D. Podskalny, Yuhui Feng, Hai Lyu, Jiemin Liao, Yuqin Wei, Michael Wernecke, Kira Leishear, Lorene M. Nelson, Thomas E. MaCurdy, Jeffrey A. Kelman, David J. Graham
Objective: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In premarketing trials in patients with Parkinson’s disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson’s disease psychosis, increase mortality in dementia
-
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain Am. J. Psychiatry (IF 19.242) Pub Date : 2022-06-15 Deborah S. Hasin, Dvora Shmulewitz, Malka Stohl, Eliana Greenstein, Efrat Aharonovich, Kenneth R. Petronis, Michael Von Korff, Samyadev Datta, Nomita Sonty, Stephen Ross, Charles Inturrisi, Michael L. Weinberger, Jennifer Scodes, Melanie M. Wall
Objective: The diagnostic criteria for opioid use disorder, originally developed for heroin, did not anticipate the surge in prescription opioid use and the resulting complexities in diagnosing prescription opioid use disorder (POUD), including differentiation of pain relief (therapeutic intent) from more common drug use motives, such as to get high or to cope with negative affect. The authors examined
-
Implementation Strategies Used and Reported in Brief Suicide Prevention Intervention Studies. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-15 Brittany N Rudd,Molly Davis,Stephanie Doupnik,Catalina Ordorica,Steven C Marcus,Rinad S Beidas
-
Mental Health Treatment Gap-The Implementation Problem as a Research Problem. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-15 Emma E McGinty,Matthew D Eisenberg
-
Who’s Afraid of Benzodiazepines? Psychother. Psychosom. (IF 25.617) Pub Date : 2022-06-09 Richard Balon
Psychother Psychosom
-
Stigmatization of Benzodiazepines: Pharmacologic and Nonpharmacologic Contributions Psychother. Psychosom. (IF 25.617) Pub Date : 2022-06-09 Edward K. Silberman
Psychother Psychosom
-
Combination Antidepressant Therapy vs Monotherapy-Further Considerations-Reply. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Jonathan Henssler,Tom Bschor,Christopher Baethge
-
Combination Antidepressant Therapy vs Monotherapy-Further Considerations. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Philip J Cowen
-
Combination Antidepressant Therapy vs Monotherapy-Further Considerations. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Klaus Munkholm,Asger Sand Paludan-Müller
-
Combination Antidepressant Therapy vs Monotherapy-Further Considerations. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Qi Wang,Liang Yao,Yaolong Chen
-
Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Holly K Hamilton,Brian J Roach,Peter M Bachman,Aysenil Belger,Ricardo E Carrión,Erica Duncan,Jason K Johannesen,Gregory A Light,Margaret A Niznikiewicz,Jean Addington,Carrie E Bearden,Kristin S Cadenhead,Barbara A Cornblatt,Thomas H McGlashan,Diana O Perkins,Ming T Tsuang,Elaine F Walker,Scott W Woods,Tyrone D Cannon,Daniel H Mathalon
Importance Although clinical criteria for identifying youth at risk for psychosis have been validated, they are not sufficiently accurate for predicting outcomes to inform major treatment decisions. The identification of biomarkers may improve outcome prediction among individuals at clinical high risk for psychosis (CHR-P). Objective To examine whether mismatch negativity (MMN) event-related potential
-
Gender Disparity in Cognitive Load and Emotional Labor-Threats to Women Physician Burnout. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-08 Ashwini Nadkarni,Jhilam Biswas
-
Intimate partner violence, suicidality, and self-harm: a probability sample survey of the general population in England Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-07 Sally McManus, Sylvia Walby, Estela Capelas Barbosa, Louis Appleby, Traolach Brugha, Paul E Bebbington, Elizabeth A Cook, Duleeka Knipe
Background Intimate partner violence (IPV) is a recognised risk factor for psychiatric disorders. There is little current evidence on IPV and self-harm and suicidality, and we therefore aimed to investigate the associations between experience of lifetime and past-year IPV with suicidal thoughts, suicide attempt, and self-harm in the past year. Methods We analysed the 2014 Adult Psychiatric Morbidity
-
Intimate partner violence: breaking the silence Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-07 Eve Griffin, Ella Arensman
Abstract not available
-
Effect of Psychiatric Advance Directives Facilitated by Peer Workers on Compulsory Admission Among People With Mental Illness: A Randomized Clinical Trial. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-06 Aurélie Tinland,Sandrine Loubière,Frederic Mougeot,Emmanuelle Jouet,Magali Pontier,Karine Baumstarck,Anderson Loundou,Nicolas Franck,Christophe Lançon,Pascal Auquier,
Importance Reducing the use of coercion in mental health care is crucial from a human rights and public health perspective. Psychiatric advance directives (PADs) are promising tools that may reduce compulsory admissions. Assessments of PADs have included facilitation by health care agents but not facilitation by peer workers. Objective To determine the efficacy of PADs facilitated by peer workers (PW-PAD)
-
Comorbid opioid use disorder and post-traumatic stress disorder Lancet Psychiatry (IF 77.056) Pub Date : 2022-06-02 Igor Elman, David Borsook
Abstract not available
-
Association of Drug Cues and Craving With Drug Use and Relapse: A Systematic Review and Meta-analysis. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-01 Nilofar Vafaie,Hedy Kober
Importance Craving, which is a strong desire for drugs, is a new DSM-5 diagnostic criterion for substance use disorders (SUDs), which are the most prevalent, costly, and deadly forms of psychopathology. Despite decades of research, the roles of drug cues and craving in drug use and relapse remain controversial. Objective To assess whether 4 types of drug cue and craving indicators, including cue exposure
-
Comorbidity and Coaggregation of Major Depressive Disorder and Bipolar Disorder and Cannabis Use Disorder in a Controlled Family Study. JAMA Psychiatry (IF 25.911) Pub Date : 2022-06-01 Courtney R Quick,Kevin P Conway,Joel Swendsen,Emma K Stapp,Lihong Cui,Kathleen R Merikangas
Importance Cannabis use disorder (CUD) is increasing in the US. Clarification of the potential mechanisms underlying the comorbidity between mood disorders and CUD may help prevent CUD. Objective To examine co-occurrence and familial aggregation of CUD and mood disorder subtypes. Design, Setting, and Participants In this cross-sectional, community-based study in the Washington, DC, metropolitan area
-
Benzodiazepines Are Efficacious and Safe for Long-Term Use: Clinical Research Data and More than Sixty Years in the Market Psychother. Psychosom. (IF 25.617) Pub Date : 2022-05-31 Antonio E. Nardi, Laiana A. Quagliato
Psychother Psychosom
-
Play Changes Us: Playing the Object, Becoming the Analyst J. Am. Psychoanal. Assoc. (IF 0.919) Pub Date : 2022-05-30 Ken Corbett
The manner in which play changes us is examined, with particular attention to the role of paradox. Sustaining paradox and illusory experiencing are held as key to the framework of psychoanalysis for patient and analyst alike. Particular attention is paid to the ways in which the analyst becomes a potential object of change through playing. The transitive hospitality of playing is examined in the treatment
-
The Limit of Intimacy and the Intimacy of Limit: Play and its Relation to the Bad Object J. Am. Psychoanal. Assoc. (IF 0.919) Pub Date : 2022-05-30 Steven H. Cooper
Attachment to the bad object has remained a durable, undertheorized clinical problem. With an extended clinical example, the experience of limit, in both patient and analyst, is examined as part of a dense undercurrent in the relationship, including transference, that gives rise to shifts in understanding the attachment to an unsatisfying internal object. Importantly, the patient’s and the analyst’s